The NECAP1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte cell line, engineered to disrupt the NECAP1 gene. This polyclonal population provides a loss-of-function model for studying NECAP1-dependent processes without clonal selection, ensuring a representation of diverse editing events while maintaining the collective behavior of the edited pool.
Raji cells are an Epstein-Barr virus (EBV)-positive human Burkitt lymphoma B cell line extensively employed in immunological and oncological research. These cells exhibit characteristic B-cell features, including surface immunoglobulin expression and the capacity for antibody production, making them a robust model for B-cell malignancies and receptor-mediated signaling studies.
NECAP1 (adaptin ear-binding clathrin-associated protein 1) is a critical component of clathrin-mediated endocytosis, functioning by bridging the AP-2 adaptor complex and clathrin triskelion at the plasma membrane. NECAP1 interacts directly with the AP2A1 and AP2B1 subunits of the AP-2 complex, as well as with clathrin heavy chain (CLTC), to facilitate endocytic vesicle formation. Its activity is regulated by phosphoinositides such as PI(4,5)P2, which anchor the AP-2 complex to the membrane, and by cargo receptors that trigger local clathrin assembly. NECAP1 collaborates with accessory proteins including PICALM and HIP1 to coordinate clathrin coat maturation. Downstream, NECAP1 function is essential for the generation of clathrin-coated vesicles and the subsequent internalization of receptors, such as the B cell receptor (BCR) and transferrin receptor, directing them toward early endosomes and ESCRT-mediated sorting.
In Raji B lymphocytes, NECAP1 knockout is expected to perturb clathrin-dependent endocytosis, potentially impairing the internalization and signaling of the BCR and other surface receptors critical for B-cell activation and antigen uptake. This disruption may influence downstream pathways relevant to lymphoma biology, providing a physiologically relevant platform to dissect the role of endocytic trafficking in B-cell malignancies and to explore the consequences of defective receptor internalization in an EBV-transformed background.
Researchers can employ these polyclonal knockout cells to investigate endocytic mechanisms in B cells, evaluate receptor internalization dynamics in lymphoma models, and conduct functional analyses of clathrin adaptor proteins. Representative assays include immunofluorescence staining for clathrin and AP-2 localization, transferrin uptake assays to quantify clathrin-mediated endocytosis, flow cytometric measurement of surface BCR levels, and co-immunoprecipitation studies to examine NECAP1 interactions with the AP-2 complex. Drug delivery studies and endocytosis inhibition experiments further leverage this model to screen for modulators of endocytic pathways. For additional technical specifications or to order these cells, please contact Ascent Research.
